Since the August 2011 release of the draft guidance document by the FDA on a risk-based approach to monitoring, there has been a lot of buzz in the industry about how to apply the approach in clinical trials. While many ask the question about how this risk-based approach may reduce the costs of clinical studies by requiring less on-site monitoring of data, it’s also important to ask what the risk is for not going on site.